Tuberculosis today

1.5 million people died from TB in 2013

95% of TB deaths occur in LMICs

China: 24% of the world’s TB cases India: 11% of the world’s TB cases

Half of the new TB cases occur in the South-East Asia and Western Pacific Regions

Africa carries the greatest proportion of new cases per population

MDG #6 to reverse the TB epidemic by 2015 has been achieved

TB mortality rates have decreased by 45% since 1990

Doing our part:
Efforts of the research-based pharmaceutical industry to fight TB

Partners in the global fight against tuberculosis

1990 2015

1.5 million people fell ill with TB in 2013

9 million people fell ill with TB in 2013

19.2% China

11% India

TB is the leading infectious killer in the world after HIV

24% of TB deaths occur in China

2nd leading infectious killer in the world after HIV

Multidrug-resistant TB (MDR-TB), extensively drug-resistant TB (XDR-TB), HIV

Developing TB cure remains a significant challenge

480,000 new cases of MDR-TB were diagnosed globally in 2013

3 million people developed MDR-TB in 2013. 9% with MDR-TB also have XDR-TB

TB is the leading cause of death among HIV patients

Only 18% of the estimated global burden of MDR-TB have been detected

Conclusions of TB and MDR-TB are not routinely an essential part of the treatment regimen

Long treatment regimen is demanding and makes successful completion difficult to achieve

Interrupted treatment increases drug resistance

• TB: 4 medicines over 6 months

• MDR-TB: > 5 medicines over 18 – 24 months

3 million

Multi-drug resistant TB (MDR-TB), extensively drug-resistant TB (XDR-TB), HIV

Long treatment regimen

Diagnostics

R&D for improved treatments and new vaccines

Expanding access to care

References:
IFPMA Health Partnerships Directory
IFPMA, Pharmaceutical R&D Projects to Prevent and Control Neglected Conditions, 2014 Status report on pharmaceutical R&D to address diseases disproportionately affecting people in low- and middle-income countries, January 2015

3 new treatments approved between 2012 and 2014

50 R&D projects for medicines

in the pipeline (10 in late stages of development, 3 in phase III)

15 global health partnerships for new medicines and vaccines

15 partnerships to increase access to treatment, diagnostics and care:

• Sharing scientific knowledge and scaling-up manufacturing capabilities in emerging markets

• Supporting door-to-door TB screenings and mHealth programs to prevent medication stock outs at remote health centres

• Accelerating social and political action to address the spread of TB

30 partnerships to increase access to TB diagnostics and care:

• 15 in India

• 15 in Africa

• 10 in South-East Asia

Expanding access to care

15 partnerships to increase access to treatment, diagnostics and care:

• 15 in India

• 15 in Africa

• 10 in South-East Asia

Expanding access to care

References:

Expanding access to care

15 partnerships to increase access to treatment, diagnostics and care:

• 15 in India

• 15 in Africa

• 10 in South-East Asia

Expanding access to care

15 partnerships to increase access to treatment, diagnostics and care:

• 15 in India

• 15 in Africa

• 10 in South-East Asia